Prenyltransferase inhibitors

Treating human ailments from cancer to parasitic infections

Joshua D. Ochocki, Mark D Distefano

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

The posttranslational modification of protein prenylation is a covalent lipid modification on the C-terminus of substrate proteins that serves to enhance membrane affinity. Oncogenic proteins such as Ras have this modification and significant effort has been placed into developing inhibitors of the prenyltransferase enzymes for clinical therapy. In addition to cancer therapy, prenyltransferase inhibitors have begun to find important therapeutic uses in other diseases, including progeria, hepatitis C and D, parasitic infections, and other maladies. This review will trace the evolution of prenyltransferase inhibitors from their initial use as cancer therapeutics to their expanded applications for other diseases.

Original languageEnglish (US)
Pages (from-to)476-492
Number of pages17
JournalMedChemComm
Volume4
Issue number3
DOIs
StatePublished - Mar 1 2013

Fingerprint

Dimethylallyltranstransferase
Parasitic Diseases
Protein Prenylation
Progeria
Hepatitis D
Enzyme Therapy
Neoplasms
Proteins
Therapeutic Uses
Post Translational Protein Processing
Hepatitis C
Membranes
Lipids
Substrates
Enzymes
Therapeutics

Cite this

Prenyltransferase inhibitors : Treating human ailments from cancer to parasitic infections. / Ochocki, Joshua D.; Distefano, Mark D.

In: MedChemComm, Vol. 4, No. 3, 01.03.2013, p. 476-492.

Research output: Contribution to journalReview article

@article{a0bd0c2e9c3a4cee969223346208b27b,
title = "Prenyltransferase inhibitors: Treating human ailments from cancer to parasitic infections",
abstract = "The posttranslational modification of protein prenylation is a covalent lipid modification on the C-terminus of substrate proteins that serves to enhance membrane affinity. Oncogenic proteins such as Ras have this modification and significant effort has been placed into developing inhibitors of the prenyltransferase enzymes for clinical therapy. In addition to cancer therapy, prenyltransferase inhibitors have begun to find important therapeutic uses in other diseases, including progeria, hepatitis C and D, parasitic infections, and other maladies. This review will trace the evolution of prenyltransferase inhibitors from their initial use as cancer therapeutics to their expanded applications for other diseases.",
author = "Ochocki, {Joshua D.} and Distefano, {Mark D}",
year = "2013",
month = "3",
day = "1",
doi = "10.1039/c2md20299a",
language = "English (US)",
volume = "4",
pages = "476--492",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",
number = "3",

}

TY - JOUR

T1 - Prenyltransferase inhibitors

T2 - Treating human ailments from cancer to parasitic infections

AU - Ochocki, Joshua D.

AU - Distefano, Mark D

PY - 2013/3/1

Y1 - 2013/3/1

N2 - The posttranslational modification of protein prenylation is a covalent lipid modification on the C-terminus of substrate proteins that serves to enhance membrane affinity. Oncogenic proteins such as Ras have this modification and significant effort has been placed into developing inhibitors of the prenyltransferase enzymes for clinical therapy. In addition to cancer therapy, prenyltransferase inhibitors have begun to find important therapeutic uses in other diseases, including progeria, hepatitis C and D, parasitic infections, and other maladies. This review will trace the evolution of prenyltransferase inhibitors from their initial use as cancer therapeutics to their expanded applications for other diseases.

AB - The posttranslational modification of protein prenylation is a covalent lipid modification on the C-terminus of substrate proteins that serves to enhance membrane affinity. Oncogenic proteins such as Ras have this modification and significant effort has been placed into developing inhibitors of the prenyltransferase enzymes for clinical therapy. In addition to cancer therapy, prenyltransferase inhibitors have begun to find important therapeutic uses in other diseases, including progeria, hepatitis C and D, parasitic infections, and other maladies. This review will trace the evolution of prenyltransferase inhibitors from their initial use as cancer therapeutics to their expanded applications for other diseases.

UR - http://www.scopus.com/inward/record.url?scp=84874505210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874505210&partnerID=8YFLogxK

U2 - 10.1039/c2md20299a

DO - 10.1039/c2md20299a

M3 - Review article

VL - 4

SP - 476

EP - 492

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 3

ER -